Bicara Therapeutics’ (BCAX) Outperform Rating Reaffirmed at Wedbush

Wedbush reissued their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note released on Wednesday morning,Benzinga reports. They currently have a $31.00 target price on the stock.

BCAX has been the subject of a number of other reports. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price objective for the company. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright boosted their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Stock Up 1.5 %

Shares of BCAX stock opened at $13.22 on Wednesday. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09. The stock’s fifty day moving average is $15.27.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, research analysts anticipate that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BCAX. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $31,000. SG Americas Securities LLC bought a new stake in Bicara Therapeutics in the fourth quarter valued at approximately $147,000. Corebridge Financial Inc. bought a new stake in Bicara Therapeutics in the fourth quarter valued at approximately $167,000. Cinctive Capital Management LP acquired a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $229,000. Finally, Barclays PLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $255,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.